1. Introduction {#sec1-jcm-09-01040}
===============

Metabolic syndrome is an important global clinical problem and a challenge for modern medicine \[[@B1-jcm-09-01040]\]. Metabolic syndrome was firstly described in specified detail in 1988 by Reaven. He suggested that it has four components: visceral obesity, hyperglycemia, arterial hypertension and dyslipidemia, described as hyper triglycerides, low HDL cholesterol fraction and high non-HDL fraction \[[@B2-jcm-09-01040],[@B3-jcm-09-01040]\].

Research that aims to explain the causes of metabolic syndrome and its epidemic occurrence is based, on the one hand, on genetic and genotypic analyses and, on the other hand, observation of influence of the external environment \[[@B4-jcm-09-01040],[@B5-jcm-09-01040]\].

Metabolic syndrome is multi-genetic. Among the genes with the strongest relationship with metabolic syndrome, CNR1---cannabinoid receptor 1 gene, LEP---leptin promoter gene, FTO---alpha-ketoglutarate-dependent dioxygenase gene, MC4R---melanocortin 4 receptor gene and VDR---vitamin D receptor stand out.

CNR1 (cannabinoid receptor 1) is a G protein-coupled receptor activated by endogenous and exogenous cannabinoids. They are found mostly in the central nervous system, in the cerebellum, nucleus accumbens and several other brain regions responsible for hunger, satiety and the reward system \[[@B6-jcm-09-01040]\]. Several specific single nucleotide polymorphisms of the CNR1 gene (located in 6q15) were found (*rs806381*, *rs806368*, *rs1049353*, *rs12720071*), as well as several possible combinations. The most popular, A to G transition in *rs1049353,* leads to higher body mass index and wider waist circumference \[[@B7-jcm-09-01040]\]. Another studied polymorphism was leptin (LEP), a hormone made mostly by adipocyte cells. It inhibits hunger and stimulates the sympathetic nervous system. Despite its seemingly straightforward effect on the human organism, current research suggests that leptin polymorphism is not a relevant obesity marker \[[@B8-jcm-09-01040]\]. Next, MC4R polymorphism was studied. Melanocortin 4 receptor is a known genetic obesity marker \[[@B9-jcm-09-01040]\]. Yet, the mechanism remains unclear, and homozygous CC (*rs17782313*) tends to be associated with higher body mass index and insulin resistance \[[@B10-jcm-09-01040]\]. Another typical obesity polymorphism is the FTO gene responsible for fat mass and an obesity-associated protein also known as alpha-ketoglutarate-dependent dioxygenase. Certain variants of this enzyme, active mostly in the central nervous system, are also correlated with higher BMI and obesity \[[@B11-jcm-09-01040]\]. Finally, VDR (vitamin D receptor) FokI polymorphism was studied. This particular receptor is responsible for most of the comprehensive activity of vitamin D. Some variants are known to be responsible for different bone density, some are correlated with renin activity and some could even directly induce obesity \[[@B12-jcm-09-01040]\].

According to current knowledge, exposure to metals may affect the development of metabolic syndrome. There are more and more reports confirming the existence of such a relationship.

Using data from the 2011--2014 National Health and Nutrition Examination Survey, Bulka et al. evaluated associations between essential and toxic metals exposure and metabolic syndrome \[[@B13-jcm-09-01040]\]. The positive correlations observed for arsenic exposure were due to an elevated prevalence of high blood pressure, low HDL cholesterol and high triglycerides among people with greater exposures. On the other hand, greater lead and cadmium co-exposures were related to a lower prevalence of dyslipidemia and abdominal obesity.

On the contrary, an analysis based on the Korea National Health and Nutrition Examination Survey (KNHANES) found that a higher prevalence of metabolic syndrome was associated with higher blood lead levels in the Korean population \[[@B14-jcm-09-01040]\].

In a study by Wang et al., blood and urinary markers of 18 heavy metals among 9537 adults in NHANES 2003--2014 were evaluated. This study suggests that cumulative exposure to heavy metals as mixtures is associated with obesity and its related to chronic conditions such as hypertension and diabetes type II \[[@B15-jcm-09-01040]\].

Luzhetskyi and co-authors proved that children with higher serum levels of cadmium and arsenic (1.4--2.0 times vs. the reference group) demonstrated 2.2 times more frequent endocrine diseases, up to 2.7 times more frequent obesity-related diseases, when compared to the reference group. Metabolic disorders in that group were associated with some lipid metabolism changes \[[@B16-jcm-09-01040]\].

Similarly, study of Kawakami et al. demonstrated that exposure to cadmium caused a reduction of adipocyte size and the modulation of adipokine expression. The reduction in adipocyte size by Cd may arise from an imbalance between lipid synthesis and lipolysis. In addition, the expression levels of leptin, adiponectin and resistin decreased in adipocytes. So, exposure to Cd may induce unusually small adipocytes and modulate the expression of adipokines differently from the case of physiologically small adipocytes, and it may accelerate the risk of developing insulin resistance and type 2 diabetes \[[@B17-jcm-09-01040]\].

Numerous data concerning potential arsenic, cadmium and lead effects on development of obesity and metabolic syndrome have inspired us to pose a hypothesis that concentrations of these metals in people occupationally exposed are related to selected gene polymorphisms and determine metabolic disorders.

The purpose of this work was to assess the influence of selected single nucleotide polymorphisms (SNPs) coding for proteins involved in development of metabolic syndrome with the previously mentioned selected gene polymorphisms on blood and urine concentration markers of lead, cadmium and arsenic in a population directly exposed to these metals.

2. Materials and Methods {#sec2-jcm-09-01040}
========================

Eighty-five people, employees of a copper smelter and refinery, were qualified to be in the study. Inclusion criteria for the study were employment in workplaces exposed to arsenic, cadmium and lead (metal concentrations \>0.1 maximum admissible concentration (MAC)) and work-related exposure to metals for at least 0.25 years. Size and quality of environmental exposure for all subjects included in the study were similar because all subjects resided in the same region. Only people who lived in the region for a long time (for at least 3 years) were included in the study group. The data and biological sample were collected in June 2016. There were 67 men and 18 women, and age ranged from 26 to 67 years. Thirty-three participants were obese, 34 of them were previously diagnosed with hypertension and 37 of them were smokers. Full clinical characteristics of the group are shown in [Table 1](#jcm-09-01040-t001){ref-type="table"}, and basic laboratory characteristics of the population are shown in [Table 2](#jcm-09-01040-t002){ref-type="table"}.

All the participants were asked to fill in a questionnaire about their medical history and lifestyle. Next, basic anthropometric measurements were taken. We also took standard urine samples and 25 mL of venous blood from each worker just after finishing their work shift to assay basic laboratory and toxicology markers as well as selected single nucleotide polymorphisms.

Blood count, fasting glucose, HbA1C, lipids (total cholesterol, HDL and LDL cholesterol, triglycerides) and calcium-phosphate balance markers (calcium, phosphorus, 25-OH-D~3~ and parathormone) were determined by standard methods in accordance with the manufacturer's instructions.

We also determined concentrations of lead (Pb-B), cadmium (Cd-B), zinc protoporphyrins in blood (ZnPP) and arsenic in urine (As-U). Blood lead and cadmium concentrations were measured by graphite furnace atomic absorption spectrometry Solaar M6 (Thermo Elemental, UK). The calibration curves of lead and cadmium were prepared with blood standards of certified reference material (BCR IRMM). Both methods are routinely monitored by determination of reference material (Recipe) and participation in an intercomparison program for toxicological analyses in biological materials, G-EQUAS. The measurement was calculated as micrograms per liter (µg/L), and the biological exposure limits were 500 µg/L for lead and 5 µg/L for cadmium according to recommendations of the National Hygiene Institute and Institute of Occupational Health. ZnPP was measured using a rapid fluorometric screening method by means of Hematofluorymeter ProtoFluor (Helena Laboratories, Beaumont, Texas, USA). Total urine arsenic concentration was measured by Hydride Generation Atomic Absorption Spectrometry (HGAAS) using the VP100 Continuous Flow Vapour System. To determine the calibration curve, the reference material ClinCal^®^ Urine Calibrator (Recipe) was used. We monitored the accuracy of the analytical method by analyzing samples of a reference material, Seronorm Trace Elements Urine (SERO AS, Oslo Norway), and participation in an intercomparison program for toxicological analyses in biological materials, G-EQUAS. The biological exposure limit proposed by the National Hygiene Institute and Institute of Occupational Health for arsenic in urine is 35 µg/L (35 µg/g creatinine).

In the study we analyzed selected single nucleotide polymorphisms (SNPs) for cannabinoid receptor 1 gene (CNR1), melanocortin 4 receptor gene (MC4R), leptin (LEP), alpha-ketoglutarate-dependent dioxygenase gene (FTO) and vitamin D receptor FokI. In the present study, the following eight SNPs were selected: *rs17782313* (T\>C), located upstream of the MC4R gene on chromosome 18q22; *rs7799039* (G\>A), a common promoter polymorphic site within the LEP gene on chromosome 7q31.3; *rs9939609* (G\>A), a SNP within intron 1 of the FTO gene on chromosome 16q12.2; *rs10735810* (FokI) (C\>T), located within exon 2 of the VDR gene on chromosome 12q11; and four polymorphisms of the CNR1 gene located on chromosome 6q15 (one intronic SNP *rs806381* A\>G, *rs806368* T\>C within 3′UTR, *rs1049353* a synonymous G\>A polymorphism (within the splicing site), and *rs12720071* A\>G, a substitution in 3′UTR). Genotyping was performed by real-time polymerase chain reaction (PCR) amplifications and a melting curve analysis using a LightSNiP typing assay (TIB-MolBiol, Berlin, Germany). Real-time PCR was carried out on a LightCycler 480 Real-Time PCR system (Roche Diagnostics, Rotkreuz, Switzerland) in accordance with the conditions recommended by the manufacturers.

The research was compliant with Good Clinical Practice guidelines, The Declaration of Helsinki and was based on consent from a local Bioethical Committee (No KB-398/2018, date: 25.06.2018).

Statistical analyses were calculated using the statistical program STATISTICA 13 (Dell Inc., Tulsa, Oklahoma, USA). For the quantitative variables, the arithmetic mean (X), the median value (Me), the standard deviation (SD) as well as the minimal (Min) and maximal (Max) values of assayed parameters were calculated in the studied groups. Distribution of variables was tested using the Lilliefors and W-Shapiro--Wilk tests. In the case of independent, quantitative variables having normal distributions, a t test for independent variables and the analysis of variances ANOVA (unifactorial parametric) were used in the further statistical analysis. The U test of Mann--Whitney or a non-parametric equivalent of Kruskal--Wallis ANOVA analysis of variance test were used in the case of variables with non-normal distributions. The significant differences between the arithmetic means were estimated using a post-hoc Newman--Keuls test. Results for the nominal variables were presented in percentages. In order to assess the relations between studied variables, a correlation analysis was performed. In the case of variables having a normal distribution, Pearson's r was calculated, and for the variables with a distribution other than normal, the Spearman's r correlation coefficient was used. Results at the level of *p* \< 0.05 were regarded as statistically significant.

3. Results {#sec3-jcm-09-01040}
==========

The mean blood calcium, phosphorus, 25-hydroxyvitamin D and parathormone concentrations in the occupationally exposed group were accordingly 9.69 ± 0.33 mg/dL, 3.43 ± 0.66 mg/dL, 20.81 ± 7.69 µg/L and 46.68 ± 20.02 ng/L. These are presented in [Table 2](#jcm-09-01040-t002){ref-type="table"}.

Arsenic concentration was 11.74 ± 9.37 µg/L, cadmium was 0.84 ± 0.80 µg/L, lead was 199.23 ± 117.02 µg/L and ZnPP was 47.94 ± 30.64 μg/dL. A total of 3.5% of employees had a urine arsenic concentration higher than the norm of the allowable concentration in biological material (determined as a maximum of 35 μg/L). Totals of 1.2% and 16.5% of workers, respectively, had a blood lead concentration and blood zinc protoporphyrin concentration higher than the norms of the allowable concentration in biological material (determined as maximums of 500 and 70 μg/L, respectively). Nobody in the study group was characterized by exceeding the norm of the permissible blood cadmium concentration. These are presented in [Table 3](#jcm-09-01040-t003){ref-type="table"}.

Distributions of alleles and genotypes of selected SNPs in the studied population are shown in [Table 4](#jcm-09-01040-t004){ref-type="table"}. Most genotypes had frequencies exceeding 10%. The CRN1 *rs12720071* GG homozygosity was the rarest and was detected in one individual only (1.2%). The other rare genotypes were MC4R *rs17782313* GG and CNR1 *rs1049353* AA homozygosity observed both in five (5.9%) cases, and the CNR1 *rs806386* CC genotype was found in seven (8.2%) cases. These distributions closely resemble those described for other European populations.

The results of comparative analyses of arsenic urine concentrations of subgroups based on genotype criteria and alleles of single nucleotide polymorphisms of genes CNR1, MC4R, LEP, FTO and VDR FokI are presented in [Table 5](#jcm-09-01040-t005){ref-type="table"}. We have proved that homozygosity AA in locus *rs806381* in the CNR1 gene is related to a statistically significant lower arsenic concentration, compared to heterozygosity AG and homozygosity GG, and the presence of allele G in this locus is associated with a significantly higher arsenic urine concentration. In locus *rs12720071* of the CNR1 gene, homozygotes GG have statistically significant higher arsenic concentrations than heterozygotes AG and homozygotes AA, and allele A in this locus can be associated with a statistically significant lower arsenic concentration. The analysis also has shown that allele A in locus *rs1049353* of the CNR1 gene can be responsible for lower arsenic concentrations, and allele G in locus *rs7799039* of gene LEP is responsible for significantly higher arsenic concentrations in the studied population.

The results of comparative analyses of cadmium blood concentrations of subgroups based on genotype criteria and alleles of single nucleotide polymorphisms of genes CNR1, MC4R, LEP, FTO and VDR FokI are presented in [Table 6](#jcm-09-01040-t006){ref-type="table"}. We have proved that allele T in locus *rs10735810* of VDR FokI gene can be a factor responsible for the significantly lower cadmium concentration in the studied population.

Similarly, the results of comparative analyses of lead blood concentrations of subgroups based on genotype criteria and alleles of single nucleotide polymorphisms of genes CNR1, MC4R, LEP, FTO and VDR FokI are presented in [Table 7](#jcm-09-01040-t007){ref-type="table"}. In the studied population, homozygotes GG in locus *rs1049353* of the CNR1 gene have a significantly higher blood lead concentration compared to heterozygotes AG and homozygotes AA. The presence of allele A in the locus is correlated with a statistically relevant lower lead blood concentration.

The results of comparative analyses of zinc protoporphyrin blood concentrations of subgroups based on genotype criteria and alleles of single nucleotide polymorphisms of genes CNR1, MC4R, LEP, FTO and VDR FokI are presented in [Table 8](#jcm-09-01040-t008){ref-type="table"}. It was proven that heterozygosity AG in locus *rs1049353* of the CNR1 gene may result in a statistically lower ZnPP concentration compared to homozygosity AA and GG, and allele A is responsible for lower ZnPP concentrations. Apart from that, we documented that allele A in locus *rs9939609* of the FTO gene is responsible for higher ZnPP concentration.

In the correlation analysis we found statistically significant, linear correlations between cadmium concentration and white blood cell count (r = 0.22, *p* = 0.040), ZnPP concentration and platelets (r = 0.25, *p* = 0.020), ZnPP concentration and phosphorus in blood (r = 0.23, *p* = 0.035) as well as ZnPP and vitamin D (r= −0.22, *p* = 0.032).

In the last part of the study, multivariate regression analysis was performed, and the following significant models were observed:

As-U = 1.330 allele G in *rs806381* gene CNR1 − 4.274 allele A in *rs1049353* gene CNR1 − 18.415 allele A in *rs12720071* gene CNR1 + 2.291 allele G in *rs7799039* gene LEP + 0.424 BMI + 0.160 age + 5.324 diabetes ± 4.877.

Cd-B = − 0.439 allele T in *rs10735810* gene VDR FokI + 0.814 smoking − 0.023 HDL cholesterol + 0.014 BMI ± 0.709.

Pb-B = − 77.411 allele A in *rs1049353* gene CNR1 + 62.804 hypertension + 82.478 diabetes − 44.553 phosphorus ± 0.709.

Based on the obtained regression models it was shown that allele G in *rs806381* gene CNR1, allele G in *rs7799039* gene LEP, higher BMI, older age and diabetes were independently associated with higher As-U concentration; while allele A in *rs1049353* gene CNR1 and allele A in *rs12720071* gene CNR1 were independently associated with lower As-U concentration. It was shown that allele T in *rs10735810* gene VDR FokI and higher HDL cholesterol concentration were independently associated with lower Cd-B concentration, while smoking and higher BMI were independently associated with higher Cd-B concentration. Finally, allele A in *rs1049353* gene CNR1 and higher phosphorus concentration were independently associated with a lower Pb-B concentration, while hypertension and diabetes were independently associated with a higher Pb-B concentration ([Table 9](#jcm-09-01040-t009){ref-type="table"}).

4. Discussion
=============

The relationship between some metals and body mass, obesity development and central hunger regulation is widely discussed and confirmed in numerous studies. Many studies focus on genetic and epigenetic mechanisms of obesity evolution. In the study of Tyrrell et al., Pb-exposed animals showed elevated hepatic triglyceride levels and increased expression of the gluconeogenic genes PEPCK and glucose-6-phosphatase \[[@B18-jcm-09-01040]\]. In cultured rat hepatoma cells, treatment with Pb stimulated PEPCK and glucose-6-phosphatase gene expression, suggesting a possible direct effect of Pb on hepatic gluconeogenic gene expression. Vidal et al. proved that elevated maternal blood Cd levels were associated with lower birth weight, and higher maternal blood Cd levels were also associated with lower methylation at the PEG3 or at the MEG3 in methylated regions of newborn DNA \[[@B19-jcm-09-01040]\].

Our study is either the first or one of the very few studies trying to determine the relationship between single nucleotide polymorphisms of genes involved in development of metabolic syndrome and toxicological parameters. Although the literature is poor, we decided to proceed with selected genes as they are the best studied in the aspect of metabolic syndrome. We found several statistically important correlations. However, we were unable to compare our results with other studies, as there have been none. On the other hand, there are numerous studies concerning studied polymorphisms and various other parameters. A comprehensive discussion of the subject will extend the framework of this research. Therefore, we decided to discuss a few examples to show the scientific and clinical importance of our study, as well as the need to continue the research.

Until now, we were unable to find other studies showing correlations between CNR1 polymorphism locus *rs1049353* and arsenic concentration. Moreover, data concerning this polymorphism and its correlation with BMI parameters are inconclusive and often contradictory \[[@B7-jcm-09-01040]\]. In our research we were able to determine a significant correlation: allele G is correlated with higher arsenic concentration. This poses the following question: what is the reason for such correlation? Do people with allele G consume more food, as some studies show \[[@B20-jcm-09-01040]\], therefore absorbing more arsenic and resulting in a higher arsenic concentration? Or, on the other hand, does a greater amount of fat tissue enable a higher arsenic concentration? Whatever the mechanism could be, we have found a genetic predisposition to higher arsenic concentration. This requires further study, especially in light of the growing obesity epidemic.

In our study we discovered that allele G in locus *rs7799039* of gene LEP is correlated with a markedly higher arsenic concentration. The authors were not able to find any other research to support or undermine our result. Nevertheless, the leptin polymorphism has been heavily studied recently. Carriers of A allele in the studied locus tend to have lower LDL and total cholesterol \[[@B21-jcm-09-01040]\]. Another recent study shows association between leptin polymorphism and coronary artery disease and hypertension \[[@B22-jcm-09-01040]\]. This finally leads us to the question about the role of arsenic in development of metabolic syndrome and cardiovascular diseases. This role is yet to be determined.

We were also able to find that allele T in locus *rs10735810* of VDR FokI gene is associated with lower cadmium concentration. Again, it seems that it is the first attempt to assess this correlation. There are single studies on metals and VDR FokI polymorphism. In the study by Szymanska-Chabowska et al., they were able to determine an association between another locus of VDR FokI gene (*rs2228570*) and concentration of lead and ZnPP \[[@B23-jcm-09-01040]\]. Our study provides more input on the matter, especially that some research suggests there is no simple connection between cadmium concentration and vitamin D concentration \[[@B24-jcm-09-01040]\].

In studied population, we were able to determine a significant correlation between the CNR1 polymorphism and lead and ZnPP concentrations. Again, this is the first research proving this relation. However, polymorphism of CNR1 is being thoroughly studied. It was found that *rs1049353* polymorphism was associated with specific changes in brain morphology as well as with evolution of positive symptoms in schizophrenia \[[@B25-jcm-09-01040]\]. This poses a question about the role of lead in the development of psychiatric disorders and brain reconstruction.

As for the linear correlation between cadmium concentration and white blood cell count, our research is compliant with many previous studies, including the most recent ones \[[@B26-jcm-09-01040],[@B27-jcm-09-01040]\]. Correlations of ZnPP concentration and platelets, ZnPP concentration and phosphorus in blood as well as ZnPP and vitamin D were not found in previous studies \[[@B23-jcm-09-01040]\].

Finally, it should be mentioned that, when analyzing multiple polymorphisms affecting a single variable (e.g., blood concentration of a particular metal), it is necessary to consider the possible compensatory effects of polymorphisms. In the current study, this compensation in individuals may be due to the effect of polymorphisms on urinary arsenic levels. If a person is a carrier of allele G in loci *rs806381* CNR1 gene and *rs7799039* LEP gene, and at the same time a carrier of allele A in loci *rs1049353* and *rs12720071* CNR1 gene, the increase in As-U concentration due to the impact of the first two alleles may be reduced as a result of the impact of the second two alleles.

The authors of this work see two main limitations of this study. First, there is little or no research to compare and confront our data. Our study was conducted with the highest standards; we found statistically significant correlations, but still, further research needs to be conducted to confirm our results. Secondly, our study is based on a relatively small population (85 persons) for genetic study. This results in poor representation of certain alleles (allele G in locus *rs12720071* CNR1---18.8%; allele C in locus *rs17782313* MC4R---37.6%). As for the first allele, we were able to obtain statistically significant correlation. If statistically important correlations are found in a relatively small group, the correlation is strong and it will be even more visible in larger groups. Finally, showing specific correlations between polymorphisms and metal concentrations is just the first step in understanding their complex role in the human organism; yet, it is an important step forward.

Relationships that we found between some genetic polymorphisms and arsenic, lead and cadmium exposure levels may indicate their role in the promotion of obesity and metabolic disorders. These metals may be one of many environmental factors that, in an unfavorable genetic constellation, contribute to higher cardiovascular risk resulting from obesity, diabetes and atherogenic lipid profile. Immunological processes modulated by vitamin D also have their impact on this risk. The relationship between lower cadmium levels and polymorphism of one of the vitamin D receptors proves that this polymorphism is beneficial in reducing cardiovascular risk in persons occupationally exposed to cadmium.

5. Conclusions {#sec5-jcm-09-01040}
==============

1.  Single nucleotide polymorphisms within genes coding for proteins involved in development of metabolic syndrome may be of prognostic value for persons directly exposed to lead, cadmium and arsenic.

2.  In the group occupationally exposed to arsenic, cadmium and lead, certain associations between polymorphisms *rs806381*, *rs1049353* and *rs12720071* of gene CNR1 and polymorphism *rs7799039* of gen LEP and arsenic concentration in urine were acquired: Allele G in locus *rs806381* CNR1 and locus *rs7799039* LEP can be responsible for higher arsenic concentrations;Allele A in locus *rs1049353* and *rs12720071* CNR1 can be responsible for lower arsenic concentrations.

3.  Cadmium concentration in blood in people occupationally exposed can be determined by polymorphism of *rs10735810* VDR FokI gene: Allele T in locus *rs10735810* VDR FokI gene can be responsible for lower cadmium concentration.

4.  In people occupationally exposed to arsenic, cadmium and lead, there are certain interactions between polymorphisms *rs1049353* gene CNR1 and *rs9939609* gene FTO and markers of lead exposure (lead and zinc protoporphyrin in blood): Allele A in locus *rs1049353* CNR1 gene can be responsible for lower lead and ZnPP concentrations;Allele A in locus *rs9939609* FTO gene can be responsible for higher ZnPP concentration.

5.  Polymorphism *rs17782813* MC4R gene, as the only one in our study, did not affect concentrations of selected markers amongst workers occupationally exposed to lead, cadmium and arsenic.
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###### 

Clinical characteristics of the study population.

  ------------------------------------------------------------------------
                             X        Me       SD       Min      Max
  -------------------------- -------- -------- -------- -------- ---------
  Age (years)                49.04    50.00    11.08    26.00    67.00

  Height (cm)                174.24   175.50   7.64     156.00   190.00

  Weight (kg)                87.39    86.00    15.93    53.00    127.00

  BMI (kg/m^2^)              28.68    27.91    4.29     19.00    40.90

  Waist circumference (cm)   100.44   100.00   12.55    72.00    125.00

  Pack-years                 465.41   340.00   386.40   60.00    1500.00

                             n        \%                         

  Number                     85       100.0                      

  Gender\                    \        \                          
  Male\                      67\      78.8\                      
  Female                     18       21.2                       

  Weight\                    \        \                          
  Normal\                    18\      21.2\                      
  Overweight\                33\      38.8\                      
  Obese                      33       38.8                       

  Smokers                    37       43.5                       

  Hypertension               34       40.0                       

  Diabetes                   10       11.8                       
  ------------------------------------------------------------------------

Max-maximal value; Me-median value; Min-minimal value; SD-standard deviation; X-arithmetic mean.

jcm-09-01040-t002_Table 2

###### 

Conventional lab tests and calcium-phosphate balance in the study population.

                              X        Me       SD       Min      Max
  --------------------------- -------- -------- -------- -------- --------
  WBC (K/µL)                  7.25     6.85     1.83     3.83     13.37
  RBC (M/µL)                  5.04     5.05     0.36     4.28     5.85
  Hemoglobin (g/dL)           15.21    15.30    1.01     12.10    17.00
  Hematocrit (%)              44.58    44.70    2.70     37.90    50.00
  Platelets (K/µL)            249.93   246.00   52.44    129.00   406.00
  Glucose (mg/dL)             96.70    93.00    20.80    68.00    181.00
  HbA1C (%)                   5.71     5.40     1.21     4.60     13.60
  Total cholesterol (mg/dL)   234.24   231.00   49.34    102.00   405.00
  HDL cholesterol (mg/dL)     51.02    49.00    11.08    27.00    86.00
  LDL cholesterol (mg/dL)     138.00   134.00   41.43    27.00    311.00
  Triglycerides (mg/dL)       236.58   196.00   155.31   46.00    824.00
  Calcium (mg/dL)             9.69     9.70     0.33     9.10     10.60
  Phosphorus (mg/dL)          3.43     3.30     0.66     2.20     5.60
  25-OH-D~3~ (µg/L)           20.81    20.49    7.69     5.21     45.00
  Parathormone (ng/L)         46.68    43.30    20.02    15.50    108.60

jcm-09-01040-t003_Table 3

###### 

Basic toxicological parameters in the study population.

                                                            X         Me       SD       Min     Max
  --------------------------------------------------------- --------- -------- -------- ------- --------
  Exposure period (years)                                   17.64     13.00    13.33    0.25    46.00
  As-U (μg/L)                                               11.74     9.93     9.37     0.27    46.15
  Cd-B (μg/L)                                               0.84      0.55     0.80     0.22    4.61
  Pb-B (μg/L)                                               199.23    193.80   117.02   22.20   520.90
  ZnPP (μg/dL)                                              47.94     35.00    30.64    21.00   160.00
                                                            ***n***   **%**                     
  Studied population                                        85        100.0                     
  As-U \>acceptable biological concentration (\>35 μg/L)    3         3.5                       
  Cd-B \>acceptable biological concentration (\>5 μg/L)     0         0.0                       
  Pb-B \>acceptable biological concentration (\>500 μg/L)   1         1.2                       
  ZnPP\>acceptable biological concentration (\>70 μg/dL)    14        16.5                      
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###### 

Selected polymorphisms of genes CNR1, MC4R, LEP, FTO and VDR FokI in the study population.

  --------------------------------------------------------------------------
  SNP             Genotype           *n*   \%      Allele      *n*   \%
  --------------- ------------------ ----- ------- ----------- ----- -------
  *rs806381*\     homozygote AA\     27\   31.8\   allele A\   70\   82.4\
  gene CNR1       heterozygote AG\   43\   50.6\   allele G    58    68.2
                  homozygote GG      15    17.6                      

  *rs806368*\     homozygote CC\     7\    8.2\    allele C\   30\   35.3\
  gene CNR1       heterozygote CT\   23\   27.1\   allele T    78    91.8
                  homozygote TT      55    64.7                      

  *rs1049353*\    homozygote AA\     5\    5.9\    allele A\   39\   45.8\
  gene CNR1       heterozygote AG\   34\   40.0\   allele G    80    94.1
                  homozygote GG      46    54.1                      

  *rs12720071*\   homozygote AA\     69\   81.2\   allele A\   84\   98.8\
  gene CNR1       heterozygote AG\   15\   17.6\   allele G    16    18.8
                  homozygote GG      1     1.2                       

  *rs17782313*\   homozygote CC\     5\    5.9\    allele C\   32\   37.6\
  gene MC4R       heterozygote CT\   27\   31.8\   allele T    80    94.1
                  homozygote TT      53    62.4                      

  *rs7799039*\    homozygote AA\     14\   16.5\   allele A\   54\   63.5\
  gene LEP        heterozygote AG\   40\   47.1\   allele G    70    82.3
                  homozygote GG      30    35.3                      

  *rs9939609*\    homozygote AA\     23\   27.1\   allele A\   66\   77.6\
  gene FTO        heterozygote AT\   43\   50.6\   allele T    62    72.4
                  homozygote TT      19    22.4                      

  *rs10735810*\   homozygote CC\     25\   29.4\   allele C\   66\   77.6\
  gene VDR FokI   heterozygote CT\   41\   48.2\   allele T    60    70.6
                  homozygote TT      19    22.4                      
  --------------------------------------------------------------------------
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###### 

Total arsenic concentration in subgroups divided according to selected polymorphisms of genes CNR1, MC4R, LEP, FTO and VDR FokI.

  ------------------------------------------------------------------------------------------------------------------
  SNP                       Genotype                                   As-U (μg/L)      Allele      As-U (μg/L)
  ------------------------- ------------------------------------------ ---------------- ----------- ----------------
  *rs806381*\               homozygote AA\                             8.58 ± 5.38\     allele A\   11.18 ± 8.72\
  gene CNR1                 heterozygote AG\                           12.81 ± 10.00\   allele G    13.24 ± 10.47
                            homozygote GG                              14.56 ± 12.11                

  AA vs. AG: *p* = 0.044\   G (GG or AG) vs. non-G (AA): *p* = 0.032                                
  AA vs. GG: *p* = 0.041                                                                            

  *rs806368*\               homozygote CC\                             11.43 ± 9.61\    allele C\   12.19 ± 11.27\
  gene CNR1                 heterozygote CT\                           12.39 ± 11.85\   allele T    11.77 ± 9.42
                            homozygote TT                              11.51 ± 8.31                 

  ns                        ns                                                                      

  *rs1049353*\              homozygote AA\                             8.99 ± 4.68\     allele A\   9.48 ± 6.66\
  gene CNR1                 heterozygote AG\                           9.56 ± 6.96\     allele G    11.92 ± 9.58
                            homozygote GG                              13.70 ± 10.91                

  ns                        A (AA or AG) vs. non-A (GG): *p* = 0.039                                

  *rs12720071*\             homozygote AA\                             11.04 ± 8.44\    allele A\   11.53 ± 9.22\
  gene CNR1                 heterozygote AG\                           13.72 ± 12.26\   allele G    14.72 ± 12.49
                            homozygote GG                              29.58 ± 0.00                 

  AA vs. GG: *p* = 0.034\   A (AA or AG) vs. non-A (GG): *p* = 0.045                                
  AG vs. GG: *p* = 0.039                                                                            

  *rs17782313*\             homozygote CC\                             14.06 ± 5.78\    allele C\   10.84 ± 8.06\
  gene MC4R                 heterozygote CT\                           10.25 ± 8.36\    allele T    11.60 ± 9.56
                            homozygote TT                              12.30 ± 10.13                

  ns                        ns                                                                      

  *rs7799039*\              homozygote AA\                             7.76 ± 5.27\     allele A\   10.98 ± 9.15\
  gene LEP                  heterozygote AG\                           12.11 ± 9.98\    allele G    12.31 ± 9.72
                            homozygote GG                              12.60 ± 9.52                 

  ns                        G (GG or AG) vs. non-G (AA): *p* = 0.043                                

  *rs9939609*\              homozygote AA\                             10.13 ± 7.14\    allele A\   12.09 ± 9.81\
  gene FTO                  heterozygote AT\                           13.10 ± 10.87\   allele T    12.31 ± 10.04
                            homozygote TT                              10.54 ± 7.79                 

  ns                        ns                                                                      

  *rs10735810*\             homozygote CC\                             13.58 ± 11.47\   allele C\   11.34 ± 9.36\
  gene VDR FokI             heterozygote CT\                           9.97 ± 7.64\     allele T    10.96 ± 8.32
                            homozygote TT                              13.21 ± 9.54                 

  ns                        ns                                                                      
  ------------------------------------------------------------------------------------------------------------------

ns-non-significant statistically.
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###### 

Cadmium concentration in subgroups divided according to selected polymorphisms of genes CNR1, MC4R, LEP, FTO and VDR FokI.

  ----------------------------------------------------------------------------------------------------
  SNP             Genotype                                   Cd-B (μg/L)    Allele      Cd-B (μg/L)
  --------------- ------------------------------------------ -------------- ----------- --------------
  *rs806381*\     homozygote AA\                             0.89 ± 0.98\   allele A\   0.86 ± 0.84\
  gene CNR1       heterozygote AG\                           0.85 ± 0.75\   allele G    0.82 ± 0.71
                  homozygote GG                              0.75 ± 0.60                

  ns              ns                                                                    

  *rs806368*\     homozygote CC\                             0.66 ± 0.35\   allele C\   0.84 ± 0.84\
  gene CNR1       heterozygote CT\                           0.89 ± 0.94\   allele T    0.86 ± 0.83
                  homozygote TT                              0.85 ± 0.79                

  ns              ns                                                                    

  *rs1049353*\    homozygote AA\                             1.08 ± 1.05\   allele A\   0.78 ± 0.67\
  gene CNR1       heterozygote AG\                           0.74 ± 0.61\   allele G    0.83 ± 0.79
                  homozygote GG                              0.90 ± 0.90                

  ns              ns                                                                    

  *rs12720071*\   homozygote AA\                             0.83 ± 0.74\   allele A\   0.85 ± 0.80\
  gene CNR1       heterozygote AG\                           0.95 ± 1.07\   allele G    0.92 ± 1.04
                  homozygote GG                              0.35 ± 0.00                

  ns              ns                                                                    

  *rs17782313*\   homozygote CC\                             1.08 ± 1.05\   allele C\   0.79 ± 0.69\
  gene MC4R       heterozygote CT\                           0.73 ± 0.61\   allele T    0.83 ± 0.79
                  homozygote TT                              0.88 ± 0.87                

  ns              ns                                                                    

  *rs7799039*\    homozygote AA\                             0.95 ± 0.75\   allele A\   0.89 ± 0.85\
  gene LEP        heterozygote AG\                           0.86 ± 0.89\   allele G    0.82 ± 0.82
                  homozygote GG                              0.77 ± 0.73                

  ns              ns                                                                    

  *rs9939609*\    homozygote AA\                             0.74 ± 0.64\   allele A\   0.79 ± 0.73\
  gene FTO        heterozygote AT\                           0.81 ± 0.78\   allele T    0.88 ± 0.85
                  homozygote TT                              1.04 ± 1.01                

  ns              ns                                                                    

  *rs10735810*\   homozygote CC\                             1.12 ± 1.17\   allele C\   0.85 ± 0.82\
  gene VDR FokI   heterozygote CT\                           0.68 ± 0.46\   allele T    0.73 ± 0.56
                  homozygote TT                              0.82 ± 0.74                

  ns              T (TT or CT) vs. non-T (CC): *p* = 0.041                              
  ----------------------------------------------------------------------------------------------------
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###### 

Lead concentration in subgroups divided according to selected polymorphisms of genes CNR1, MC4R, LEP, FTO and VDR FokI.

  ----------------------------------------------------------------------------------------------------------------------
  SNP                       Genotype                                   Pb-B (μg/L)        Allele      Pb-B (μg/L)
  ------------------------- ------------------------------------------ ------------------ ----------- ------------------
  *rs806381*\               homozygote AA\                             180.50 ± 97.72\    allele A\   194.23 ± 123.09\
  gene CNR1                 heterozygote AG\                           202.85 ± 137.05\   allele G    207.95 ± 124.82
                            homozygote GG                              222.58 ± 82.32                 

  ns                        ns                                                                        

  *rs806368*\               homozygote CC\                             207.09 ± 50.81\    allele C\   180.20 ± 101.05\
  gene CNR1                 heterozygote CT\                           172.01 ± 111.61\   allele T    198.53 ± 121.37
                            homozygote TT                              209.61 ± 124.52                

  ns                        ns                                                                        

  *rs1049353*\              homozygote AA\                             171.58 ± 117.21\   allele A\   161.48 ± 107.35\
  gene CNR1                 heterozygote AG\                           160.00 ± 107.64\   allele G    200.96 ± 117.53
                            homozygote GG                              231.23 ± 116.39                

  AG vs. GG: *p* = 0.006\   A (AA or AG) vs. non-A (GG): *p* = 0.005                                  
  AA vs. GG: *p* = 0.045                                                                              

  *rs12720071*\             homozygote AA\                             193.85 ± 115.37\   allele A\   199.31 ± 117.72\
  gene CNR1                 heterozygote AG\                           224.46 ± 129.17\   allele G    222.44 ± 125.05
                            homozygote GG                              192.20 ± 0.00                  

  ns                        ns                                                                        

  *rs17782313*\             homozygote CC\                             244.16 ± 99.42\    allele C\   185.52 ± 114.97\
  gene MC4R                 heterozygote CT\                           174.66 ± 116.00\   allele T    196.42 ± 118.00
                            homozygote TT                              207.51 ± 118.55                

  ns                        ns                                                                        

  *rs7799039*\              homozygote AA\                             208.89 ± 137.93\   allele A\   197.13 ± 123.09\
  gene LEP                  heterozygote AG\                           193.02 ± 119.09\   allele G    196.51 ± 114.08
                            homozygote GG                              201.17 ± 108.88                

  ns                        ns                                                                        

  *rs9939609*\              homozygote AA\                             205.35 ± 107.83\   allele A\   206.01 ± 119.89\
  gene FTO                  heterozygote AT\                           206.36 ± 127.10\   allele T    196.96 ± 121.01
                            homozygote TT                              175.69 ± 106.02                

  ns                        ns                                                                        

  *rs10735810*\             homozygote CC\                             224.20 ± 139.97\   allele C\   194.11 ± 121.91\
  gene VDR FokI             heterozygote CT\                           175.76 ± 107.16\   allele T    188.83 ± 105.60
                            homozygote TT                              217.04 ± 99.02                 

  ns                        ns                                                                        
  ----------------------------------------------------------------------------------------------------------------------
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###### 

Zinc protoporphyrins (ZnPP) concentration in subgroups divided according to selected polymorphisms of genes CNR1, MC4R, LEP, FTO and VDR FokI.

  ------------------------------------------------------------------------------------------------------------------
  SNP                       Genotype                                   ZnPP (μg/dL)     Allele      ZnPP (μg/dL)
  ------------------------- ------------------------------------------ ---------------- ----------- ----------------
  *rs806381*\               homozygote AA\                             42.48 ± 25.15\   allele A\   45.99 ± 27.84\
  gene CNR1                 heterozygote AG\                           48.19 ± 29.47\   allele G    50.48 ± 32.78
                            homozygote GG                              57.07 ± 41.30                

  ns                        ns                                                                      

  *rs806368*\               homozygote CC\                             64.86 ± 48.64\   allele C\   47.10 ± 32.03\
  gene CNR1                 heterozygote CT\                           41.70 ± 24.01\   allele T    46.42 ± 28.49
                            homozygote TT                              48.40 ± 30.15                

  ns                        ns                                                                      

  *rs1049353*\              homozygote AA\                             56.60 ± 42.48\   allele A\   39.64 ± 23.11\
  gene CNR1                 heterozygote AG\                           37.15 ± 18.61\   allele G    47.40 ± 30.03
                            homozygote GG                              54.98 ± 34.51                

  AG vs. GG: *p* = 0.009\   A (AA or AG) vs. non-A (GG): *p*=0.020                                  
  AA vs. AG: *p* = 0.037                                                                            

  *rs12720071*\             homozygote AA\                             47.38 ± 30.92\   allele A\   47.39 ± 30.40\
  gene CNR1                 heterozygote AG\                           47.47 ± 28.91\   allele G    50.38 ± 30.26
                            homozygote GG                              94.00 ± 0.00                 

  ns                        ns                                                                      

  *rs17782313*\             homozygote CC\                             51.20 ± 43.25\   allele C\   45.88 ± 32.92\
  gene MC4R                 heterozygote CT\                           44.89 ± 31.59\   allele T    47.74 ± 30.05
                            homozygote TT                              49.19 ± 29.43                

  ns                        ns                                                                      

  *rs7799039*\              homozygote AA\                             53.57 ± 32.82\   allele A\   46.53 ± 30.42\
  gene LEP                  heterozygote AG\                           42.75 ± 25.72\   allele G    45.56 ± 27.82
                            homozygote GG                              51.57 ± 35.59                

  ns                        ns                                                                      

  *rs9939609*\              homozygote AA\                             52.26 ± 37.44\   allele A\   51.08 ± 32.33\
  gene FTO                  heterozygote AT\                           50.44 ± 29.70\   allele T    46.34 ± 27.89
                            homozygote TT                              37.05 ± 21.13                

  ns                        A (AA or AT) vs. non-A (TT): *p* = 0.038                                

  *rs10735810*\             homozygote CC\                             52.96 ± 29.89\   allele C\   46.26 ± 29.02\
  gene VDR FokI             heterozygote CT\                           42.17 ± 28.05\   allele T    45.85 ± 30.95
                            homozygote TT                              53.79 ± 35.97                

  ns                        ns                                                                      
  ------------------------------------------------------------------------------------------------------------------

jcm-09-01040-t009_Table 9

###### 

Results of estimation for the final model obtained from multivariate regression analysis.

                                       Independent Variable                     Regression Coefficient   Standard error of Regression Coefficient   *p*-Value   *p* Value of the Model   Standard Error of the Model
  ------------------------------------ ---------------------------------------- ------------------------ ------------------------------------------ ----------- ------------------------ -----------------------------
  model for As-U (μg/L)                allele G in *rs806381* gene CNR1         1.330                    0.666                                      0.041       0.043                    4.877
  allele A in *rs1049353* gene CNR1    −4.274                                   2.095                    0.037                                                                           
  allele A in *rs12720071* gene CNR1   −18.415                                  9.136                    0.037                                                                           
  allele G in *rs7799039* gene LEP     2.291                                    1.072                    0.045                                                                           
  BMI (kg/m^2^)                        0.424                                    0.173                    0.025                                                                           
  age (years)                          0.160                                    0.070                    0.015                                                                           
  diabetes                             5.324                                    2.269                    0.026                                                                           
  model for Cd-B (μg/L)                allele T in *rs10735810* gene VDR FokI   −0.439                   0.187                                      0.022       0.006                    0.709
  smoking                              0.814                                    0.184                    0.001                                                                           
  HDL cholesterol (mg/dL)              −0.023                                   0.011                    0.045                                                                           
  BMI (kg/m2)                          0.014                                    0.002                    0.046                                                                           
  model for Pb-B (μg/L)                allele A in *rs1049353* gene CNR1        −77.411                  26.320                                     0.004       0.014                    112.131
  hypertension                         62.804                                   39.182                   0.014                                                                           
  diabetes                             82.478                                   58.742                   0.016                                                                           
  phosphorus (mg/dL)                   −44.553                                  21.391                   0.041                                                                           
